A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Study Summary

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

Conditions

Unresectable Locally Advanced Metastatic Cancers Relapsed/Refractory Lymphomas

Interventions / Drugs

REC-1245

View on ClinicalTrials.gov ↗

Sponsor

RXRX

Recursion Pharmaceuticals

AI Drug Discovery

D38/100

Study Details

Enrollment85 participants

Primary Completion—

Lead SponsorRecursion Pharmaceuticals Inc.

Data Retrieved2026-04-11 04:26:31.746410+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.